If CYDY wants to go ahead full stream with mono, GvHD and cancer, the milestone payment upon BLA submission won't suffice. At the current enrollment pace, interim results for GvHD and cancer will take quite a bit of time. Question is whether they really want to run with 10% speed until revenue in Q2, or not, - can they find financial means to accelerate their progress in these trials before approval?

I guess it all depends to which level the SP will jump upon announcement of a deal and BLA submission, i.e whether they can raise at much higher levels and without warrants.